Key Points
- Director Arani Bose sold 7,500 shares on Nov. 21 at an average price of $290.56 for a total of $2,179,200, reducing his stake by 2.58% to 282,761 shares per an SEC filing.
- Penumbra beat quarterly expectations with $0.97 EPS vs. $0.90 and revenue of $354.7M versus $340.8M, a 17.8% year-over-year revenue increase.
- Analysts have an average rating of "Moderate Buy" with a consensus target of $305.69; the stock trades near its 52-week high (current open ~$298.85) and the company has a market cap of ~$11.7B.
Penumbra, Inc. (NYSE:PEN - Get Free Report) Director Arani Bose sold 7,500 shares of the stock in a transaction on Friday, November 21st. The stock was sold at an average price of $290.56, for a total value of $2,179,200.00. Following the transaction, the director owned 282,761 shares of the company's stock, valued at $82,159,036.16. The trade was a 2.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Penumbra Trading Up 0.2%
Shares of PEN opened at $298.85 on Wednesday. Penumbra, Inc. has a fifty-two week low of $221.26 and a fifty-two week high of $310.00. The business has a 50-day moving average of $257.96 and a 200 day moving average of $257.40. The firm has a market cap of $11.70 billion, a P/E ratio of 79.48, a price-to-earnings-growth ratio of 2.10 and a beta of 0.51. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.04 and a current ratio of 6.75.
Penumbra (NYSE:PEN - Get Free Report) last released its quarterly earnings data on Wednesday, November 5th. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.90 by $0.07. The business had revenue of $354.69 million for the quarter, compared to the consensus estimate of $340.77 million. Penumbra had a net margin of 11.54% and a return on equity of 11.55%. The company's revenue was up 17.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.85 earnings per share. Penumbra has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Penumbra, Inc. will post 3.67 EPS for the current year.
Hedge Funds Weigh In On Penumbra
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Penumbra in the 1st quarter worth $2,148,000. Cetera Investment Advisers lifted its holdings in shares of Penumbra by 56.9% during the 1st quarter. Cetera Investment Advisers now owns 2,757 shares of the company's stock worth $737,000 after acquiring an additional 1,000 shares during the last quarter. LPL Financial LLC grew its position in Penumbra by 167.8% in the first quarter. LPL Financial LLC now owns 25,408 shares of the company's stock worth $6,794,000 after acquiring an additional 15,922 shares in the last quarter. Fielder Capital Group LLC bought a new position in Penumbra in the first quarter valued at $209,000. Finally, Meeder Asset Management Inc. increased its stake in Penumbra by 1,966.7% in the first quarter. Meeder Asset Management Inc. now owns 372 shares of the company's stock valued at $99,000 after acquiring an additional 354 shares during the last quarter. Hedge funds and other institutional investors own 88.88% of the company's stock.
Analysts Set New Price Targets
A number of equities research analysts have recently issued reports on PEN shares. Weiss Ratings reissued a "hold (c+)" rating on shares of Penumbra in a report on Wednesday, November 19th. Robert W. Baird upped their target price on shares of Penumbra from $283.00 to $285.00 and gave the stock an "outperform" rating in a report on Wednesday, July 30th. Royal Bank Of Canada lowered their target price on shares of Penumbra from $330.00 to $325.00 and set an "outperform" rating on the stock in a research note on Wednesday, July 30th. BTIG Research reissued a "buy" rating and issued a $320.00 price target on shares of Penumbra in a report on Monday, October 27th. Finally, Wall Street Zen lowered shares of Penumbra from a "buy" rating to a "hold" rating in a research report on Saturday, November 1st. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $305.69.
Check Out Our Latest Research Report on Penumbra
About Penumbra
(
Get Free Report)
Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
